首頁 > 市場調查報告書 > 製藥

癌症婦科治療

外陰癌市場規模、佔有率和成長分析（按癌症類型、治療方法、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1919127

外陰癌市場規模、佔有率和成長分析（按癌症類型、治療方法、最終用戶和地區分類）—2026-2033年產業預測

Vulvar Cancer Market Size, Share, and Growth Analysis, By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma), By Treatment Type (Chemotherapy, Surgery), By End Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月29日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球外陰癌市場規模將達到 5.953 億美元，到 2025 年將成長至 6.5245 億美元，到 2033 年將成長至 13.5841 億美元，在預測期（2026-2033 年）內複合成長率為 9.6%。

全球外陰癌市場正經歷顯著成長，主要受發病率上升的推動，尤其是在老齡化人口和HPV感染人群中。新型標靶治療、免疫腫瘤藥物以及包括人工智慧引導切片檢查在內的先進診斷技術的出現，正在推動市場擴張。旨在改善癌症治療的宣傳活動和政府舉措，提高了全球早期診斷和治療的可及性，進一步促進了市場成長。免疫療法的重大進展正在改變治療格局，而這得益於針對HPV相關癌症的大量研究。這凸顯了標靶介入在塑造未來治療方案和推動產業成長方面發揮的關鍵作用。這種不斷變化的環境為外陰癌市場的相關人員帶來了巨大的機會。

全球外陰癌市場促進因素

全球外陰癌市場的主要促進因素之一是女性對婦科癌症的認知度不斷提高，以及早期檢測的普及。有關外陰癌症狀和風險的教育和資訊傳播力度加大，促使更多女性接受身體檢查和篩檢。這種認知度的提高不僅有助於早期診斷，也推動了對包括藥物治療、手術介入和支持性護理在內的各種治療方案的需求。此外，醫療保健服務的改善和診斷技術的進步也進一步促進了外陰癌市場的成長，為創新治療方案的開發創造了更有利的環境。

限制全球外陰癌市場的因素

全球外陰癌市場的主要限制因素之一是公眾和醫療專業人員對該疾病缺乏認知和了解。由於外陰癌是一種相對罕見的疾病，與較常見的癌症相比，其研究經費有限，治療選擇也較少。這種認知不足往往導致診斷和治療延誤，進而對患者的預後產生負面影響。此外，圍繞女性生殖健康話題的文化偏見會進一步阻礙大眾對該疾病的認知，並使女性不願就醫，最終限制了外陰癌診斷和治療方法市場的整體成長。

全球外陰癌市場趨勢

全球外陰癌市場正經歷重大變革，這主要得益於免疫療法（尤其是免疫查核點抑制劑）的加速普及。這種治療方法利用人體自身的免疫系統精準辨識並攻擊癌細胞，為進行性外陰癌患者帶來了新的希望。隨著臨床試驗展現出令人鼓舞的結果，醫療機構越來越傾向將免疫療法通訊協定置於傳統治療方法之上，重塑了病患管理策略。人們對外陰癌的認知不斷提高，以及標靶治療的進步，進一步推動了市場的動態，預示著能夠改善患者預後和生活品質的創新治療方案將擁有廣闊的前景。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Merck & Co., Inc.（MSD）
GlaxoSmithKline（GSK）
Bristol Myers Squibb（BMS）
Regeneron Pharmaceuticals, Inc.
Sanofi SA
F. Hoffmann-La Roche Ltd
AstraZeneca PLC
Inovio Pharmaceuticals, Inc.
Incyte Corporation
Shanghai Bovax Biotechnology Co., Ltd.
Xencor, Inc.
Transgene SA
GI Innovation, Inc.
TScan Therapeutics, Inc.
Marengo Therapeutics, Inc.
SCG Cell Therapy Pte. Ltd.
HRYZ Biotech Co.
Chimerix
Novartis AG
Eli Lilly and Companya

結論與建議

簡介目錄

Product Code: SQMIG35D2379

Global Vulvar Cancer Market size was valued at USD 595.3 million in 2024 and is poised to grow from USD 652.45 million in 2025 to USD 1358.41 million by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global vulvar cancer market is experiencing significant growth driven by increasing incidence rates, especially among aging populations and those affected by HPV. The emergence of new targeted therapies, immuno-oncology drugs, and advanced diagnostic technologies, including AI-guided biopsies, is catalyzing market expansion. Heightened awareness campaigns and government initiatives aimed at enhancing cancer treatment are further propelling growth by improving access to early diagnosis and care worldwide. Noteworthy advancements in immunotherapy have transformed treatment landscapes, underlined by extensive research focused on HPV-related cancers, which underscores the critical role of targeted interventions in shaping future therapeutic options and driving industry growth. This evolving landscape presents substantial opportunities for stakeholders within the vulvar cancer market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vulvar Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vulvar Cancer Market Segments Analysis

Global Vulvar Cancer Market is segmented by Cancer Type, Treatment Type, End Users and region. Based on Cancer Type, the market is segmented into Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma and Basal Cell Carcinoma. Based on Treatment Type, the market is segmented into Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Therapy and Biologic Therapy. Based on End Users, the market is segmented into Hospitals and Clinics, Research and Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vulvar Cancer Market

One key market driver for the global vulvar cancer market is the increasing awareness and early detection of gynecological cancers among women. Enhanced educational initiatives and the dissemination of information regarding vulvar cancer symptoms and risks have led to more women seeking medical consultations and screenings. This heightened awareness not only contributes to earlier diagnosis but also fosters a greater demand for treatment options, including medical therapies, surgical interventions, and supportive care. Additionally, improvements in healthcare access and advancements in diagnostic technologies are further propelling the growth of the vulvar cancer market, creating a more robust landscape for innovative treatment solutions.

Restraints in the Global Vulvar Cancer Market

One significant market restraint for the global vulvar cancer market is the lack of awareness and understanding about the disease among the general population as well as healthcare professionals. Vulvar cancer is relatively rare, leading to limited research funding and fewer treatment options compared to more prevalent cancers. This lack of awareness often results in delayed diagnosis and treatment, adversely affecting patient outcomes. Additionally, cultural stigmas surrounding discussions of female reproductive health further hinder education efforts and may discourage women from seeking medical help for symptoms, ultimately restricting the overall market growth for vulvar cancer diagnostics and therapies.

Market Trends of the Global Vulvar Cancer Market

The global vulvar cancer market is witnessing a significant shift driven by the accelerated adoption of immunotherapy, particularly immune checkpoint inhibitors. This therapeutic approach harnesses the body's immune system to accurately identify and combat cancer cells, offering new hope for patients with advanced vulvar cancer. As clinical trials demonstrate promising results, healthcare providers increasingly prioritize immunotherapy protocols over traditional treatments, reshaping patient management strategies. The growing awareness of vulvar cancer and advancements in targeted therapies are further propelling market dynamics, suggesting a robust future for innovative treatment solutions that enhance patient outcomes and quality of life.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Vulvar Cancer Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Vulvar Squamous Cell Carcinoma
Vulvar Melanoma
Adenocarcinoma
Basal Cell Carcinoma

Global Vulvar Cancer Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Chemotherapy
Surgery
Laser Surgery
Excision
Skinning Vulvectomy
Radical Vulvectomy
Radiation Therapy
Biologic Therapy

Global Vulvar Cancer Market Size by End Users & CAGR (2026-2033)

Market Overview
Hospitals and Clinics
Research and Academic Institutes
Others

Global Vulvar Cancer Market Size & CAGR (2026-2033)

North America (Cancer Type, Treatment Type, End Users)
- US
- Canada
Europe (Cancer Type, Treatment Type, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Cancer Type, Treatment Type, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Cancer Type, Treatment Type, End Users)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Cancer Type, Treatment Type, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Merck & Co., Inc. (MSD)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (BMS)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Bovax Biotechnology Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GI Innovation, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TScan Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Marengo Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SCG Cell Therapy Pte. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HRYZ Biotech Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chimerix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Companya
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments